neuromyelitis optica spectrum disorder, NMOSD
Conditions
Interventions
Observation group:None
Sponsors
Xi'an No.1 Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Diagnosed with AQP-4 antibody positive NMOSD (meeting the diagnostic criteria of the 2015 International Neuro-Ophtalmology Society); 2. Clear AQP-4 antibody status record at enrollment; 3. Treated with satralizumab and completed 3 induction treatments; 4. Follow-up of >=6 months, and can provide clear prognosis or relapse information.
Exclusion criteria
Exclusion criteria: 1. Both serum and cerebrospinal fluid AQP-4 antibodies are negative; 2. Serum or cerebrospinal fluid MOG antibodies are positive; 3. Prior concomitant medication: received B cell depletion agents within 6 months before baseline (excluding cases where B cells have returned to normal levels) or IL-6 receptor antagonists within 2 months; received other immunosuppressive therapy before baseline within the expected pharmacodynamics effect window; 4. Key data missing; 5. Refused follow-up and assessment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Annual recurrence rate, ARR;Expanded Disability Status Scale, EDSS; | — |
Secondary
| Measure | Time frame |
|---|---|
| IL-6;immune globulin G; | — |
Countries
China
Contacts
Public ContactSongdi Wu
Xi'an No.1 Hospital
Outcome results
None listed